Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
1
50%
Ph early_phase_1
1
50%

Phase Distribution

2

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Early Phase 1First-in-human
1(50.0%)
Phase 1Safety & dosage
1(50.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Completed(1)
Terminated(1)

Detailed Status

Withdrawn1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
100.0%
Most Advanced
Early Phase 1

Trials by Phase

Early Phase 11 (50.0%)
Phase 11 (50.0%)

Trials by Status

withdrawn150%
completed150%

Recent Activity

0 active trials
Showing 2 of 2
withdrawnphase_1

Study of OB-002 in Patients With Refractory Metastatic Cancer

NCT05940844
completedearly_phase_1

OB-002H Gel Administered Vaginally and Rectally in HIV-1 Seronegative Adults

NCT04791007

Clinical Trials (2)

Showing 2 of 2 trials
NCT05940844Phase 1

Study of OB-002 in Patients With Refractory Metastatic Cancer

Withdrawn
NCT04791007Early Phase 1

OB-002H Gel Administered Vaginally and Rectally in HIV-1 Seronegative Adults

Completed

All 2 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
2